Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
October 8, 2015
Verastem Announces Reduction of Workforce
September 28, 2015
Verastem Stops Enrollment Due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma
September 24, 2015
Verastem Announces New Research Published in the Journal Cell That Highlights the Potential of FAK Inhibition to Enhance the Efficacy of Anti-Tumor Immunotherapy
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.